CSPC Pharmaceutical (HKG:1093) received a milestone payment of $10 million from AstraZeneca on Wednesday under a 2025 research collaboration agreement, according to a same-day Hong Kong bourse filing.
The move was related to the exercise of a license option for one of the pre-clinical candidate programs under the contract, signifying that the relevant R&D work is progressing as planned.